SCHEMBL4299713

SCHEMBL4299713

CCOC(=O)[C@](C)(N)Cc1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.55
HTR2A P28223 2/20 0.55
CYP1A2 P05177 2/20 0.55
PMP22 Q01453 2/20 0.55
PPARA Q07869 2/20 0.55
ABCB11 O95342 1/20 0.55
TSHR P16473 1/20 0.55
OPRK1 P41145 1/20 0.53
SLC6A2 P23975 1/20 0.51
SLC6A4 P31645 1/20 0.51
HRH1 P35367 1/20 0.51
HTR2B P41595 1/20 0.51
CHRNA4 P43681 1/20 0.51
SLC6A3 Q01959 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
NFKB1 P19838 1/20 0.51
CYP2C19 P33261 1/20 0.51
LMNA P02545 1/20 0.50
NLRP3 Q96P20 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1773480 1.00 CYP3A4 (0.55) CYP3A4HTR2ACYP1A2PMP22PPARA
SCHEMBL1811459 0.93 CYP3A4 (0.49) CYP3A4HTR2ACYP1A2PMP22PPARA
SCHEMBL9386400 0.86 BLM (0.63) CYP3A4HTR2ACYP1A2PMP22PPARA
SCHEMBL9386398 0.86 BLM (0.63) CYP3A4HTR2ACYP1A2PMP22PPARA
SCHEMBL5205928 0.84 MMP8 (0.48) CYP3A4HTR2ACYP1A2PMP22PPARA
SCHEMBL5205923 0.84 MMP8 (0.48) CYP3A4HTR2ACYP1A2PMP22PPARA
SCHEMBL6974147 0.84 MMP8 (0.48) CYP3A4HTR2ACYP1A2PMP22PPARA
SCHEMBL10684512 0.84 MMP8 (0.61) TSHRSLC6A2LMNABLMMMP8
SCHEMBL1831636 0.84 MMP8 (0.61) TSHRSLC6A2LMNABLMMMP8
SCHEMBL2557165 0.84 CYP3A4 (0.58) CYP3A4HTR2ACYP1A2PMP22PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8614316-B2 Optically active quaternary ammonium salt having axial asymmetry and process for producing α-amino acid and derivative thereof with the same NAGASE & CO., LTD. (JP) 2013-12-24 US disclosed
EP-2484667-A1 Optically active quaternary ammonium salt having axial asymmetry and process for producing alpha-amino acid and derivative thereof with the same NAGASE & COMPANY, LTD. (JP) 2012-08-08 EP disclosed
EP-2484667-A1 Optically active quaternary ammonium salt having axial asymmetry and process for producing alpha-amino acid and derivative thereof with the same NAGASE & COMPANY, LTD. (JP) 2012-08-08 EP disclosed
US-20090270614-A1 OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME NAGASE & CO., LTD. (JP) 2009-10-29 US disclosed
US-20090270614-A1 OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME NAGASE & CO., LTD. (JP) 2009-10-29 US disclosed
EP-1870403-A1 OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME NAGASE & COMPANY, LTD. (JP) 2007-12-26 EP disclosed
EP-1870403-A1 OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME NAGASE & COMPANY, LTD. (JP) 2007-12-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270614-A1 OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME BCAT1, BCAT2, AADAT CYP3A4 3412/4885HTR2A 2379/4885CYP1A2 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.